Advanced Accelerator Applications SA

Tweet this page
<
2021
2022
2023
>
No longer registered as of 15 Mar 2024 - Registration as it was on 14 Mar 2023
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

200,000€ - 299,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

0.5 Fte (2)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Advanced Accelerator Applications SA   (AAA)

    EU Transparency Register

    893121642569-12 First registered on 30 Apr 2021

    Goals / Remit

    AAA is an innovative medicines company focused on the development of products for targeted radioligand therapy and precision radioligand imaging. AAA currently markets 1 targeted radioligand therapy in oncology and several precision imaging products. We also have an active research and development pipeline of investigational drugs using radiolabeled targeting molecules in multiple cancer types. We are able to generate or reliably source radioisotopes such as fluorine 18 (F-18) and lutetium 177 (Lu-177), and conduct much of our own research and development, in addition to having in-house commercial manufacturing. AAA currently has a total of 31 sites in 12 countries, incl: 19 production facilities in 8 countries (in Europe and the U.S.) and 6 sites with R&D activity. All of our manufacturing facilities conform to cGMP.

    Main EU files targeted

    Health policy and radioprotection policy.
    Potentially also industrial and R&D policies.
    In 2023, specifically:
    -EU Beating Cancer Plan
    -SAMIRA Action Plan
    -Pharmaceutical Strategy

    Address

    Head Office
    Rue de la Tour de l’Ile 4
    Geneva 1204
    SWITZERLAND
    EU Office
    Rue de la Tour de l’Ile 4
    Geneva 1204
    SWITZERLAND

    Website

    http://www.adacap.com

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    25%2

    Lobbyists (Full time equivalent)

    0.5

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    AAA is a member of Nuclear Medicine Europe (trade association)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    200,000€ - 299,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    european cancer organization 50,000€ - 99,999€
    rhode public policy (rpp) 100,000€ - 199,999€
    nuclear medicine of europe 25,000€ - 49,999€
    sparc europe 25,000€ - 49,999€

    Intermediaries for current year

    None declared

    Closed year Costs

    200,000€ - 299,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    None

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard